Macular Degeneration clinical trials at UC Davis

7 in progress, 4 open to eligible people

Showing trials for

  • Goji vs. Fiber on Macular Degeneration

    “Are you at risk for age-related macular degeneration?”

    open to eligible people ages 65-95

    The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.

    Sacramento, California

  • Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

    open to eligible people ages 50 years and up

    Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

    Sacramento, California and other locations

  • Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

    “Help Advance Research for Geographic Atrophy – Join a Clinical Trial Evaluating New Treatments”

    open to eligible people ages 50-85

    This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone or in combination with pozelimab compared to those treated with placebo. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug(s) - How much study drug(s) are in the blood at different times - Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

    Sacramento, California and other locations

  • Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

    open to eligible people ages 50-89

    ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.

    Sacramento, California and other locations

  • Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

    Sorry, in progress, not accepting new patients

    This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.

    Sacramento, California

  • Post-Approval Study of the Implantable Miniature Telescope

    Sorry, accepting new patients by invitation only

    The objective of the PAS-01 study is to assess the safety of the intraocular as measured by the cumulative incidence of patients who within 5 years after implantation experience persistent vision-impairing corneal edema (corneal edema leading to persistent loss of best corrected distance visual acuity >2 lines from pre-surgery baseline level). The study will test the null hypothesis that the percentage of patients who experience persistent vision-impairing corneal edema is >17% against the alternative that the percentage is <17%. The null hypothesis will be rejected if the upper bound of the two-sided 95% confidence integral for the observed percentage is <17%.

    Sacramento, California and other locations

  • Progression of Intermediate Age-Related Macular Degeneration

    Sorry, in progress, not accepting new patients

    This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational study is to assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical endpoint. The study will consist of an observation period of approximately 3 years (~144 weeks) for participants.

    Sacramento, California and other locations

Our lead scientists for Macular Degeneration research studies include .

Last updated: